SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:6b3b1873-d506-41ee-bb11-40100c077fff"
 

Search: onr:"swepub:oai:lup.lub.lu.se:6b3b1873-d506-41ee-bb11-40100c077fff" > Ticagrelor versus C...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Hiatt, William RUniversity of Colorado (author)

Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease

  • Article/chapterEnglish2017

Publisher, publication year, extent ...

  • 2017

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:6b3b1873-d506-41ee-bb11-40100c077fff
  • https://lup.lub.lu.se/record/6b3b1873-d506-41ee-bb11-40100c077fffURI
  • https://doi.org/10.1056/NEJMoa1611688DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-334966URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:134885761URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Martin Björck (Uppsala Universitet, Institutionen för kirurgiska vetenskaper, kärlkirurgi) var National Lead Investigator för den svenska delen av studien och en av dessa ”Investigators”
  • BACKGROUND: Peripheral artery disease is considered to be a manifestation of systemic atherosclerosis with associated adverse cardiovascular and limb events. Data from previous trials have suggested that patients receiving clopidogrel monotherapy had a lower risk of cardiovascular events than those receiving aspirin. We wanted to compare clopidogrel with ticagrelor, a potent antiplatelet agent, in patients with peripheral artery disease.METHODS: In this double-blind, event-driven trial, we randomly assigned 13,885 patients with symptomatic peripheral artery disease to receive monotherapy with ticagrelor (90 mg twice daily) or clopidogrel (75 mg once daily). Patients were eligible if they had an ankle-brachial index (ABI) of 0.80 or less or had undergone previous revascularization of the lower limbs. The primary efficacy end point was a composite of adjudicated cardiovascular death, myocardial infarction, or ischemic stroke. The primary safety end point was major bleeding. The median follow-up was 30 months.RESULTS: The median age of the patients was 66 years, and 72% were men; 43% were enrolled on the basis of the ABI and 57% on the basis of previous revascularization. The mean baseline ABI in all patients was 0.71, 76.6% of the patients had claudication, and 4.6% had critical limb ischemia. The primary efficacy end point occurred in 751 of 6930 patients (10.8%) receiving ticagrelor and in 740 of 6955 (10.6%) receiving clopidogrel (hazard ratio, 1.02; 95% confidence interval [CI], 0.92 to 1.13; P=0.65). In each group, acute limb ischemia occurred in 1.7% of the patients (hazard ratio, 1.03; 95% CI, 0.79 to 1.33; P=0.85) and major bleeding in 1.6% (hazard ratio, 1.10; 95% CI, 0.84 to 1.43; P=0.49).CONCLUSIONS: In patients with symptomatic peripheral artery disease, ticagrelor was not shown to be superior to clopidogrel for the reduction of cardiovascular events. Major bleeding occurred at similar rates among the patients in the two trial groups. (Funded by AstraZeneca; EUCLID ClinicalTrials.gov number, NCT01732822 .).

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Fowkes, F Gerry RUniversity of Edinburgh (author)
  • Heizer, GretchenDuke University (author)
  • Berger, Jeffrey SNew York University (author)
  • Baumgartner, IrisUniversity of Bern (author)
  • Held, PeterAstraZeneca, Sweden (author)
  • Katona, Brian GAstraZeneca, US (author)
  • Mahaffey, Kenneth WStanford University (author)
  • Norgren, LarsÖrebro University (author)
  • Jones, W SchuylerDuke University (author)
  • Blomster, Juuso (author)
  • Millegård, Marcus (author)
  • Reist, Craig (author)
  • Patel, Manesh R (author)
  • Gottsäter, AndersLund University,Lunds universitet,Internmedicin - epidemiologi,Forskargrupper vid Lunds universitet,Internal Medicine - Epidemiology,Lund University Research Groups(Swepub:lu)medf-ago (creator_code:cre_t)
  • University of ColoradoUniversity of Edinburgh (creator_code:org_t)
  • EUCLID Trial Steering Committee and Investigators

Related titles

  • In:The New England journal of medicine376, s. 32-400028-47931533-4406

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view